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ABSTRACT
An integrative literature review was conducted to synthesize available publications regarding the potential use of serological 
tests in leprosy programs. We searched the databases Literatura Latino-Americana e do Caribe em Ciências da Saúde, Índice 
Bibliográfico Espanhol em Ciências da Saúde, Acervo da Biblioteca da Organização Pan-Americana da Saúde, Medical 
Literature Analysis and Retrieval System Online, Hanseníase, National Library of Medicine, Scopus, Ovid, Cinahl, and Web 
of Science for articles investigating the use of serological tests for antibodies against phenolic glycolipid-I (PGL-I), ML0405, 
ML2331, leprosy IDRI diagnostic-1 (LID-1), and natural disaccharide octyl-leprosy IDRI diagnostic-1 (NDO-LID). From an 
initial pool of 3.514 articles, 40 full-length articles fulfilled our inclusion criteria. Based on these papers, we concluded that 
these antibodies can be used to assist in diagnosing leprosy, detecting neuritis, monitoring therapeutic efficacy, and monitoring 
household contacts or at-risk populations in leprosy-endemic areas. Thus, available data suggest that serological tests could 
contribute substantially to leprosy management.
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INTRODUCTION
Leprosy persists as a significant public health issue in many 
countries, especially those that are socially and economically 
underdeveloped. In 2013, the World Health Organization 
(WHO) was notified of 215.656 new cases in 102 countries, with 
India and Brazil accounting for 58.9% and 14.4% of new cases, 
respectively(1). Among the goals set by the WHO to achieve 
by end of 2015 was to reduce, by at least 35% compared to 
2010, new cases among children under 15 years of age, as well 
new cases with grade 2 disability. These goals were intended 
to stimulate activities aimed at achieving early diagnosis and 
providing timely treatment with multidrug therapy, thereby 
helping to both reduce new cases and minimize transmission 
of Mycobacterium leprae(2).
At present, diagnosis is predominantly based on clinical 
assessment, and therefore depends on recognition of characteristic 
symptoms. However, investment in new technologies may be 
necessary to facilitate early diagnosis and to achieve WHO 
goals. Indeed, while tests such as skin slit smear, Mitsuda test, 
and histological analyses can accelerate diagnosis, none are 
100% sensitive or specific(3). In addition, a sensitive and specific 
test to classify leprosy as either paucibacillary or multibacillary 
is critical in selecting the most appropriate treatment regimen. 
Thus, the current diagnostic challenge is to identify or develop 
a point-of-care test that can contribute to or facilitate early 
diagnosis and classification. Toward this end, immunological 
tests are being evaluated. Among the most advanced tools in 
development are tests to detect antibodies against phenolic 
glycolipid-I (PGL-I), or its di- and trisaccharide analogs NDO 
and NTP, respectively. Additional diagnostic markers include 
antibodies against Leprosy IDRI Diagnostic-1 (LID-1), which 
is a fusion of the ml0405 and ml2331 gene products(4), as 
well as antibodies against NDO-LID, a conjugate of natural 
disaccharide octyl (NDO) and LID(5). In this study, we mined 
the available peer-reviewed scientific literature to assess the 
value of serological tests in leprosy control programs. 
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INTEGRATIVE LITERATURE REVIEW
In integrative literature review, relevant publications are 
collected and summarized in a systematic manner, with the intent 
of consolidating present knowledge of the subject of interest(6). 
To guide the review, we asked the following question: “How 
have serology tests for antibodies against PGL-I, ML0405, 
ML2331, LID-1, and NDO-LID been used to manage leprosy?”
We searched for articles in the databases Literatura Latino-
Americana e do Caribe em Ciências da Saúde (LILACS), 
National Library of Medicine (PUBMED), Medical Literature 
Analysis and Retrieval System Online (MEDLINE), Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), 
Índice Bibliográfico Espanhol em Ciências da Saúde (IBECS), 
Acervo da Biblioteca da Organização Pan-Americana da Saúde 
(PAHO), Hanseníase (HANSEN), SCOPUS, OVID, and Web 
of Science. 
To search in LILACS, IBECS, and PAHO of the Descritores 
em Ciência da Saúde, the following descriptors were used: “LID-
1”, “NDO-LID”, “PGL-I”, “PGL-1”, “ML0405”, “ML2331”, 
“Recombinant Proteins”, “Recombinant Fusion Proteins”, 
“Fusion Proteins”, “Glycolipids”, “Antigens, Bacterial”, 
“Immunoglobulin G”, “Immunoglobulin M”, “gamma-
Globulins”, “Immunoglobulin”, “Antibodies, Bacterial”, 
“IgM”, “IgG”, “ELISA”, “Serologic Tests”, “Serodiagnosis”, 
“Agglutination Tests”, “Enzyme-Linked Immunosorbent 
Assay”, and “Mycobacterium leprae”. The descriptors were used 
in English, Portuguese, and Spanish, alone or in combination.
In PUBMED, MEDLINE, and CINAHL the following 
search terms from Medical Subject Headings were used: 
“Recombinant Proteins”, “Recombinant Fusion Proteins”, 
“Glycolipids”, “Antigens, Bacterial”, “LID-1”, “NDO-LID”, 
“PGL-I”, “PGL-1”, “Recombinant Proteins”, “ML0405”, 
“ML2331”, “Immunoglobulin G”, “Immunoglobulin M”, 
“Antibodies, Bacterial”, “Gamma Globulin”, “IgM”, “IgG”, 
“Antibody”, “Serologic Tests”, “Agglutination Tests”, 
“Enzyme-Linked Immunosorbent Assay”, “ELISA”, “ML 
FLOW”, “Mycobacterium leprae”, “Leprosy”, and “Hansen’s 
Disease”.
To be considered for review, papers should have been 
published between January 2002 and January 2015 in 
Portuguese, English, or Spanish; should be available as full-
text in electronic format; and should contain at least one of 
the following terms in the title in any of the three languages: 
“serology”, “seroprevalence”, “seropositivity”, “subclinical 
infection”, “antibody”, “antigen”, “immunological”, “ML 
Flow”, “laboratory test”, “PGL-I”, “PGL-1”, “LID-1”, “NDO-
LID”, “protein”, “ML0405”, and “ML 2331”. In addition, we 
considered only those articles with level of evidence 1, 2, 3, and 4, 
as defined in the classification of evidence hierarchical system(7). 
Article ID, methodological characteristics, methodological 
rigor, and soundness of results were collected from all candidate 
articles by four researchers, following an instrument adapted 
from Ursi(8). Articles were formally and finally selected by 
consensus based on suitability and preliminary data from all 
four researchers. Descriptive analysis was then performed to 
summarize the main findings of each article with regard to the 
following themes: “use of serological assays in diagnosis”, 
“surveillance of household contacts and at-risk populations”, 
“value of serological tools in assessing multidrug therapy”, 
and “potential relationship between serum antibodies and M. 
leprae transmission”.
ARTICLE SELECTION
Based on the question “How have serology tests detecting 
anti-PGL-I, anti-ML0405, anti-ML2331, anti-LID-1 and anti-
NDO-LID antibodies been used in leprosy?”, we identified a total 
of 3.514 articles, of which 2.554 were duplicated among databases. 
Duplicates were excluded, along with a further 856 articles excluded 
based on title, 33 based on abstract, and 31 based on full text, 
either because the articles did not meet inclusion criteria, or were 
otherwise unsuitable for the objectives of the review. In the end, 
40 articles were considered for final integrative review (Figure 1).
USE OF SEROLOGICAL ASSAYS IN DIAGNOSIS 
OF LEPROSY
Testing for anti-PGL-I can help classify leprosy(9) (10) (11) (12) (13) 
(14) (15) into paucibacillary and multibacillary forms(5) (15) (16) (17) (18) (19) 
(20) (21) (22) and facilitate differential diagnosis (23) (Table 1). When 
used in Brazil as an additional tool for classification, a rapid anti-
PGL-I test called ML Flow reduced the number of cases treated as 
multibacillary, thus reducing the use of anti-mycobacterial drugs, 
as well as the amount of case management required. Hence, the 
test provided a direct benefit during treatment(24). 
Testing for antibodies against recombinant ML0405, 
ML2331, and LID-1 antigens can also assist in diagnosis and 
classification(5) (17) (25) (26)  (Table 1). In particular, antibodies 
against LID-1 can be used as an immunological marker for 
leprosy(27), more specifically of the multibacillary presentation(17). 
Indeed, reports indicate that anti-LID-1 can detect leprosy 6-8 
months before clinical symptoms manifest(4). Thus, screening 
for anti-LID-1 in the general population or in populations at 
greatest risk of M. leprae infection could potentially accelerate 
treatment, and reduce transmission by effectively reducing the 
number of individuals with high bacterial load(4). 
Tests for antibodies against the NDO-LID conjugate are also 
essentially tests for antibodies against both PGL-I and LID-1. Thus, 
such tests can increase the sensitivity and specificity of diagnosis 
over levels achieved by serological tests for anti-PGL-I only. 
Indeed, tests based on NDO-LID assist in rapid and consistent 
detection and monitoring of multibacillary leprosy(5) (28) (29) (Table 1).
Antibodies in the sera may be measured by techniques such as 
enzyme linked immunosorbent assay (ELISA)(4) (5) (16) (17) (18) (28) (29), 
and lateral flow tests such as ML Flow(9) (10) (11) (12) (13) (16) (18) (19) (20) (24) 
and NDO-LID® rapid test(28). Indeed, laboratory-based ELISA has 
been used to analyze seroreactivity against PGL-I(4) (5) (17), LID-1(4) (5) 
(17), ML0405, ML2331(4) (17), and NDO-LID(5) (29). On the other hand, 
ML Flow is a simple, fast(9), and reliable tool to detect anti-PGL-I(10) 
using NTP as antigen, a semi-synthetic trisaccharide analog of PGL-I 
that is chemically linked to either bovine or human serum albumin(11). 
Finally, the NDO-LID® rapid test is used to detect antibodies against 
both the LID-1 chimeric fusion protein and NDO, a disaccharide 
analog of PGL-I(28). Importantly, ML Flow and NDO-LID® 
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FIGURE 1 - Selection of studies for integrative review.
rapid test are simple serological tests that can readily be used 
by healthcare professionals providing primary care, and, unlike 
ELISA, are not dependent upon laboratory analysis.
SURVEILLANCE OF HOUSEHOLD CONTACTS 
AND AT-RISK POPULATIONS
Measurement of immunoglobulin M (IgM) antibodies 
against PGL-I may be useful to assess exposure to M. leprae. As 
anti-PGL-I is a marker for those at a higher risk of developing 
leprosy, screening could be used for early diagnosis in 
household contacts(12) (21) (30) (31), and for detection of individuals 
with subclinical, asymptomatic M. leprae infection(18) (21) (32) 
(Table 2). Indeed, household contacts who test positive for 
anti-PGL-I are at increased risk of developing either form 
of leprosy(33) (34), especially in households with an index case 
of multibacillary leprosy(21). In particular, the estimated risk of 
developing multibacillary leprosy is 34.4 times higher when 
antibodies against PGL-I are detected(33). Similarly, evaluation 
of IgM and immunoglobulin G (IgG) antibodies against the 
NDO-LID conjugate allows detection of a significant number 
of M. leprae-infected individuals in early stages of disease 
development(29). Further, accurate measurement of antibody 
titers may also be useful, because increased titers of anti-
PGL-I (NDO-BSA) and anti-LID-1 could potentially identify 
household contacts that require careful monitoring or clinical 
examination(35) (Table 2). On balance, the data suggest that 
simultaneous assessment of multiple antibodies to detect possible 
M. leprae infection may identify contacts at greatest risk of 
becoming ill(36).
People at risk of developing leprosy should be carefully 
monitored(34) (37) (Table 2) or, to prevent new cases, subjected 
to intervention strategies such as post-exposure prophylaxis(21) (37). 
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TABLE 1 - Use of serological tests as an auxiliary tool to diagnose leprosy.
Antigen	 Major	findings/comments	 References
PGL-I	native	and/or	mimetic	 Helps detect early-stage leprosy 39
 Helps classify patients correctly 9, 10, 12, 13, 14, 15, 24
 Assists in differentiating between MB and PB forms 5, 15, 16, 17, 18, 19, 20, 21, 22, 24, 44 
 Assists in differential diagnosis 23
 Assists in identifying patients with high bacterial load 11
 Helps diagnose MB leprosy 25, 43
ML0405 Improves performance of anti-PGL-I tests 25
ML2331 Assists in diagnosis and classification 5, 17, 26
LID-1 Assists in diagnosis 27
 Assists in diagnosis, specifically of MB leprosy 17, 25
 Assists in detecting early-stage leprosy 4
 Improves performance of anti-PGL-I tests 25
NDO-LID Assists in rapid and consistent detection of MB leprosy 5, 28
 Assists in patient monitoring 29
 Increases sensitivity and specificity of anti-PGL-I tests 29
PGL-I: phenolic glycolipid-I; ML: Mycobacterium leprae; LID-1: leprosy IDRI diagnostic-1; NDO-LID: natural disaccharide octyl-leprosy IDRI diagnostic-1; 
MB: multibacillary; PB: paucibacillary. 
TABLE 2 - Use of serological tests in surveillance programs.
Antigen	 Major	findings/comments	 References
PGL-I	native	and/or	mimetic	 Used to evaluate exposure to antigen  30
 Assists in identifying individuals with subclinical infection  18, 21, 32
 Assists in early diagnosis among household contacts  30, 43
 Can identify contacts at high risk of developing leprosy  11, 14, 21, 31, 33, 34, 36
 Can identify broad groups most at risk of becoming ill  37
 Can assist in monitoring household contacts  35
 Can indicate need for clinical examination  35
 Assists in identifying school-age children with higher risk of developing leprosy  38
 Assists in estimating potential of M. leprae transmission 37
ML0405 Enhances PGL-I tests in identifying contacts at greater risk of developing leprosy  40
ML2331  
LID-1 Can be used to detect M. leprae infection 41
 Assists in identifying household contacts that require careful surveillance 35
 Can indicate need for clinical examination 35
NDO-LID Allows detection of early-stage infection  29
 Can be used to monitor suspected cases of M. leprae infection  29
PGL-I: phenolic glycolipid-I; ML: Mycobacterium leprae; LID-1: leprosy IDRI diagnostic-1; NDO-LID: natural disaccharide octyl-leprosy IDRI diagnostic-1; 
M.: Mycobacterim.
Fabri ACOC et al. - Serological tests for leprosy
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TABLE 3 - Use of serological tests in therapy and neuritis.
Antigens	 Major	finding/comments	 References
PGL-I	native	and/or	mimetic	 Assists in selecting the most appropriate multidrug therapy 3, 10, 18, 24, 42
 Can be considered as marker of re-infection and indicate long-term high risk of leprosy 26
 Allows evaluation of multidrug therapy 4, 26
 Enables assessment of bacterial load after treatment 9
 Helps detect nerve damage 45
ML0405 Allows evaluation of multidrug therapy
ML2331 Indicates long-term high risk of leprosy 4, 26, 27
LID-1 Can be considered as markers of re-infection 26
PGL-I: phenolic glycolipid-I; ML: Mycobacterium leprae; LID-1: leprosy IDRI diagnostic-1.
Indeed, household contacts with subclinical M. leprae infection 
could actively transmit M. leprae to susceptible individuals(21), 
and are thus a concern. Detection of antibodies against PGL-I can 
identify school-age children with increased risk of developing 
leprosy(38) (Table 2). Indeed, seroepidemiology studies of anti-
PGL-I and the prevalence of previously undetected leprosy among 
household contacts and school children suggest that active M. leprae 
infection and sustained circulation persist in many regions. Notably, 
clinical and serological surveys among students in hyperendemic 
areas help identify patients at an earlier stage of disease than 
otherwise would be achieved. Fortunately, diagnoses are typically 
provided before physical disabilities develop, while treatment and 
education help prevent further infections in the community(39).
In addition, detection of antibodies against recombinantly 
expressed M. leprae proteins enhances PGL-I-based identification 
of household contacts at greater risk of developing leprosy(40) 
(Table 2). Indeed, the LID-1 antigen may be used as a screening 
tool(41), while evaluation of antibodies against NDO-LID can 
improve surveillance, facilitate referral to an expert(29), and help 
develop new interventions and treatments.
We note that in hyperendemic areas, leprosy control 
activities should extend beyond household contacts and into 
the general population, which might also be considered at high 
risk(31). The possibility and feasibility of carrying out large-scale 
screening campaigns to detect antibodies against PGL-I, LID-1, 
and NDO-LID should therefore be investigated as a means to 
identify M. leprae-infected individuals(5). Regular and sustained 
monitoring of suspected cases is also suggested(29).
Since successive evaluation of antibodies may contribute 
to early diagnosis, rapid tests based on PGL-I, LID-1, and 
NDO-LID antigens should be incorporated into primary health 
care services in order to detect household contacts and other 
individuals at risk of becoming sick. It also appears prudent 
to extend these assays into clinical surveys in schools and the 
general population in leprosy endemic areas.
SEROLOGICAL TOOLS IN EVALUATING 
MULTIDRUG THERAPY 
As noted, serological tests can help classify leprosy patients, 
and thus help determine the most appropriate multidrug therapy 
regimen(3) (10) (18) (42) (Table 3). As serological evaluations correlate 
well with bacterial index(3) (42) (43), these tests can inform treatment-
related decisions when bacilloscopy is not available(13) (44). Indeed, 
serological assays could reduce the risk of undertreatment and 
supplant bacilloscopy, a more invasive and risky procedures(13). 
When used as basis for selecting the multidrug therapy regimen, 
serological anti-PGL-I tests reduce nerve damage and associated 
physical disabilities(18). Corollarily, as patients with impaired 
nerve function typically have high levels of anti-PGL-I IgM 
and IgG, serological evaluation may also assist in identifying 
individuals with nerve damage (Table 3). The association between 
high antibody titers and nerve damage highlights the need to detect 
and treat serologically positive individuals as soon as possible(45). 
Serum antibodies can also be a useful measure of the 
effectiveness of treatments(4) (26) (27) (Table 3). Indeed, antibody 
titers decline after multidrug therapy(4) (18) (27) (29), with IgG against 
LID-1 diminishing faster than IgM against PGL-I or NDO-
BSA(26). Hence, serological assays could be used to indirectly 
assess bacterial load after completion of treatment, and may 
detect persistent bacterial multiplication, which could result in 
reactions or relapse(9). Re-emergence or increase of IgM and IgG 
titers can also indicate reinfection, and persistent seropositivity 
may indicate high risk of symptoms appearing even years later(26) 
(Table 3). Further, measurement of anti-PGL-I in patients with 
reactions after treatment helps to identify individuals that should 
undergo further treatment, prevention, or monitoring. Leprosy 
control personnel should thus evaluate the possibility of using 
serological assays in patients who are at risk for developing 
reactions after multidrug therapy, because these tools can 
support new strategies for prevention and disease control(9).
SERUM ANTIBODIES AS MEASURES  
OF MYCOBACTERIUM LEPRAE TRANSMISSION 
POTENTIAL
Detection of serum anti-PGL-I enhances diagnostic accuracy, 
guides treatment, and thereby reduces transmission of M. leprae 
from patients(10) (36). Anti-PGL-I screening to identify, monitor, 
and treat contacts or other people most at risk of developing 
leprosy may also reduce M. leprae transmission(12). Indeed, 
individuals living in proximity to patients with anti-PGL-I 
Rev Soc Bras Med Trop 49(2):158-164 Mar-Apr, 2016
  163
have increased likelihood of themselves producing antibodies 
to M. leprae. Thus, assessing serological status with simple 
tests such as ML flow can provide a more reliable assessment 
of transmission potential, as well as broaden the definition of 
contact(37) (Table 2). Detection of antibodies against LID-1, 
or against both PGL-I and LID-1, has similar benefits(5) (28). In 
the end, simple serological tools could enable monitoring at a 
greater frequency than can be achieved with clinical exams, 
and this is an important consideration for the success of any 
leprosy control program.
In summary, the published literature indicates that serological 
tests for antibodies against PGL-I, ML0405, and ML2331 
(in the form of conjugated antigens LID-1 or NDO-LID) can 
assist in the diagnosis and classification of leprosy. Furthermore, 
assessment of these antibodies may also help determine the 
choice of multidrug therapy, as well as monitor its effectiveness. 
Moreover, anti-PGL-I testing may assist in identifying individuals 
with nerve damage, as well as those more likely to be affected by 
reaction episodes after bacteriological clearance.
Most people infected with M. leprae do not develop clinical 
symptoms. Therefore, a major challenge for leprosy control 
and elimination is to identify individuals who will become ill, 
and to take steps to prevent illness(38). Fortunately, detection 
of antibodies against LID-1 and NDO-LID can facilitate early 
diagnosis of multibacillary leprosy. Indeed, serological tests 
for antibodies against PGL-I, ML0405, ML2331, LID-1, and 
NDO-LID can contribute to surveillance of both household 
contacts and the general population.
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